Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies.

PubWeight™: 1.04‹?› | Rank: Top 15%

🔗 View Article (PMID 22147207)

Published in Clin Rheumatol on November 18, 2011

Authors

Anna K Wong1, Susan Kerkoutian, Jonathan Said, Hooman Rashidi, Sheeja T Pullarkat

Author Affiliations

1: Department of Pathology and Laboratory Medicine, UCSD School of Medicine, San Diego, CA, USA.

Articles citing this

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis (2013) 1.19

Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. Ann Oncol (2013) 0.89

A case of rheumatoid arthritis and limited systemic sclerosis overlap successfully treated with tocilizumab for arthritis and concomitant generalized lymphadenopathy and primary biliary cirrhosis. Case Rep Rheumatol (2014) 0.79

Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate. Virchows Arch (2013) 0.79

Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses. Clin Rheumatol (2015) 0.77

Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab. JAAD Case Rep (2015) 0.75

Fas/Fas-Ligand Interaction As a Mechanism of Immune Homeostasis and β-Cell Cytotoxicity: Enforcement Rather Than Neutralization for Treatment of Type 1 Diabetes. Front Immunol (2017) 0.75

Bilateral Vocal Cord Carcinoma in a Sarcoidosis Patient during Infliximab Therapy. Case Rep Pulmonol (2013) 0.75

TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review. World J Gastroenterol (2014) 0.75

Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders. Virchows Arch (2016) 0.75

Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther (2017) 0.75

Articles cited by this

Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet (2004) 12.62

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum (2006) 9.37

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med (1997) 8.65

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50

Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med (2001) 7.41

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum (2004) 6.55

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22

Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum (2004) 4.57

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum (2002) 4.15

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol (2003) 3.47

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum (2006) 2.54

Rheumatoid arthritis and cancer risk. Eur J Cancer (1996) 2.44

Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum (2003) 2.17

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis (2006) 1.77

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64

A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol (2006) 1.46

Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol (2004) 1.46

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis (2007) 1.37

Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis (2001) 1.35

Incidence of cancer among men with the Felty syndrome. Ann Intern Med (1994) 0.92

Articles by these authors

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res (2011) 2.05

Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma (2008) 1.91

IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res (2011) 1.87

Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75

Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology (2013) 1.71

KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol (2004) 1.69

Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer (2010) 1.61

Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol (2003) 1.59

Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol (2009) 1.55

Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica (2011) 1.48

Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer (2003) 1.29

Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila) (2011) 1.23

Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res (2004) 1.21

Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med (2009) 1.20

Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer (2010) 1.18

Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res (2008) 1.16

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood (2013) 1.12

Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer (2009) 1.12

Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci (2008) 1.10

Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol (2003) 1.10

Trefoil factor 3 is overexpressed in human prostate cancer. Prostate (2004) 1.09

Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol (2008) 1.09

Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res (2006) 1.09

CD3-positive large B-cell lymphoma. Am J Surg Pathol (2009) 1.03

Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of castleman disease at low risk for HIV infection. Am J Clin Pathol (2002) 1.03

Mimics of cutaneous lymphoma: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol (2013) 1.03

Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci (2008) 1.03

KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states. Am J Surg Pathol (2013) 1.00

Primary central nervous system histiocytic sarcoma presenting as a postradiation sarcoma: case report and literature review. Hum Pathol (2013) 0.99

Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma. Clin Cancer Res (2012) 0.96

Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study. BJU Int (2009) 0.96

Primary effusion lymphoma: genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration. J Pathol (2010) 0.95

Post-transplant multiple myeloma in a pediatric renal transplant patient. Pediatr Blood Cancer (2006) 0.95

Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol (2009) 0.94

Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood (2008) 0.94

Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death. Blood (2006) 0.93

Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients. Pediatr Blood Cancer (2013) 0.93

Vitamin D3 analogs stimulate hair growth in nude mice. Endocrinology (2002) 0.92

Polyphenols in brewed green tea inhibit prostate tumor xenograft growth by localizing to the tumor and decreasing oxidative stress and angiogenesis. J Nutr Biochem (2012) 0.92

Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood (2012) 0.91

Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother (2009) 0.90

Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol (2007) 0.89

Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid. Clin Infect Dis (2009) 0.87

Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation. Mod Pathol (2003) 0.87

Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab. Ann Hematol (2005) 0.86

A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy. Cancer Prev Res (Phila) (2013) 0.86

Epstein-Barr virus patterns in US Burkitt lymphoma tumors from the SEER residual tissue repository during 1979-2009. APMIS (2013) 0.83

Recommendations for the reporting of lymphoid neoplasms: a report from the Association of Directors of Anatomic and Surgical Pathology. Mod Pathol (2004) 0.83

LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int J Oncol (2006) 0.83

A case of hemolytic anemia and severe thrombocytopenia related to histiocytic sarcoma. Leuk Res (2010) 0.83

Adult leukemic synovitis is associated with leukemia of monocytic differentiation. J Clin Rheumatol (2011) 0.83

Malignant melanoma with neural differentiation: an exceptional case report and brief review of the pertinent literature. Am J Dermatopathol (2014) 0.82

Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res (2003) 0.82

Protein partners of C/EBPepsilon. Exp Hematol (2004) 0.82

Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments. Mol Imaging Biol (2013) 0.82

Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood (2007) 0.82

IGFBP-3 nuclear localization predicts human prostate cancer recurrence. Horm Cancer (2012) 0.81

Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol (2012) 0.81

Systemic mastocytosis with plasma cell dyscrasia: report of a case. Leuk Res (2007) 0.81

Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders. Am J Surg Pathol (2014) 0.81

Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. Am J Surg Pathol (2016) 0.81

Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy. Cancer Prev Res (Phila) (2013) 0.79

Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles County. J Med Virol (2012) 0.78

Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions. Hum Pathol (2013) 0.78

Primary carcinoid tumor of urinary bladder discovered on pelvic magnetic resonance imaging. Urology (2012) 0.78

Diagnostic confusion resulting from CD56 expression by cutaneous myeloid sarcoma. Rare Tumors (2009) 0.77

Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. Am J Surg Pathol (2014) 0.77

Recommendations for the reporting of lymphoid neoplasms: a report from the Association of Directors of Anatomic and Surgical Pathology. The Ad Hoc Committee on reporting of lymphoid neoplasms. Hum Pathol (2002) 0.77

Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. J Endocrinol (2011) 0.77

Primary dural marginal zone lymphoma in a woman with inflammatory breast cancer. J Clin Oncol (2008) 0.76

Stem cell transplantation in primary myelofibrosis of childhood. J Pediatr Hematol Oncol (2013) 0.76

Histopathology of brow fat in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg (2012) 0.76

Association of Ig/BCL6 translocations with germinal center B lymphocytes in human lymphoid tissues: implications for malignant transformation. Blood (2006) 0.75

Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival. AIDS (2015) 0.75

Splenic hamartomas in Alagille syndrome: case report and literature review. Fetal Pediatr Pathol (2014) 0.75

Type II bare lymphocyte syndrome: role of peripheral blood flow cytometry and utility of stem cell transplant in treatment. J Pediatr Hematol Oncol (2015) 0.75

Acral lymphomatoid papulosis associated with poikilodermatous mycosis fungoides. Dermatol Online J (2013) 0.75

Pathology quiz case 1. IgG4-related sialadenitis as a presenting symptom of IgG4-related disease. JAMA Otolaryngol Head Neck Surg (2013) 0.75

High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Leuk Lymphoma (2008) 0.75

Accelerated phase of Chediak-Higashi syndrome. Blood (2012) 0.75

Combined Megaloblastic and Sideroblastic Anemia in an Infant Fed With Goat's Milk. J Pediatr Hematol Oncol (2017) 0.75

A patient with primary cardiac lymphoma. Mol Imaging Biol (2002) 0.75